Translate Bio Announces Key Leadership Additions and Promotions
19 avr. 2021 07h30 HE | Translate Bio, Inc.
-- Seasoned healthcare executive, Brendan Smith, appointed as Chief Financial Officer, bringingstrategic operations and financial leadership -- -- Appointments enhance capabilities across pulmonary...
TBIO.jpg
Translate Bio Announces Publication of Preclinical Results of COVID-19 mRNA Vaccine Candidate MRT5500 in npj Vaccines
19 avr. 2021 07h30 HE | Translate Bio, Inc.
-- Multiple antigen constructs, including the construct used in MRT5500, induced potent neutralizing antibodies against SARS-CoV-2 in preclinical studies in multiple species -- -- Efficacy...
TBIO.jpg
Translate Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
07 avr. 2021 16h05 HE | Translate Bio, Inc.
LEXINGTON, Mass., April 07, 2021 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
TBIO.jpg
Translate Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
23 mars 2021 16h30 HE | Translate Bio, Inc.
LEXINGTON, Mass., March 23, 2021 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
TBIO.jpg
Translate Bio Appoints Dr. Rand Sutherland as President
22 mars 2021 07h30 HE | Translate Bio, Inc.
-- 20 years of combined industry, medical and academic expertise in pulmonary and rare disease to support continued advancement of mRNA therapeutic pipeline -- LEXINGTON, Mass., March 22, 2021 ...
TBIO.jpg
Translate Bio Announces Results from Second Interim Data Analysis from Ongoing Phase 1/2 Clinical Trial of MRT5005 in Patients with Cystic Fibrosis (CF)
17 mars 2021 16h05 HE | Translate Bio, Inc.
-- First inhaled mRNA therapeutic delivered in multiple doses to the lungs of CF patients is generally safe and well tolerated; no observed pattern of increases in ppFEV1 -- -- Data supports...
TBIO.jpg
Sanofi and Translate Bio Initiate Phase 1/2 Clinical Trial of mRNA COVID-19 Vaccine Candidate
12 mars 2021 01h00 HE | Translate Bio, Inc.
-- Clinical trial to assess safety, immune response and reactogenicity, after preclinical data showed high neutralizing antibody levels -- -- Expected to enroll 415 participants; interim results...
TBIO.jpg
Translate Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
03 mars 2021 16h05 HE | Translate Bio, Inc.
LEXINGTON, Mass., March 03, 2021 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
TBIO.jpg
Translate Bio Announces Fourth Quarter and Full Year 2020 Financial Results and Highlights Recent Progress
25 févr. 2021 16h05 HE | Translate Bio, Inc.
-- Additional interim data expected in early Q2 from Phase 1/2 clinical trial of MRT5005 for the treatment of cystic fibrosis (CF) -- -- Two infectious disease mRNA vaccine programs expected to enter...
TBIO.jpg
Translate Bio to Present at the SVB Leerink Virtual 10th Annual Global Healthcare Conference
18 févr. 2021 07h30 HE | Translate Bio, Inc.
LEXINGTON, Mass., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...